Remarkably, in the last decade, many other types of cancers were shown to be ROR1 positive (Zhang et al., 2012) and to overexpress is still under investigation. ROR1, would show an excellent response to a combination therapy with venetoclax and monoclonal antibodies against ROR1, since both drugs target the same malignant cells that have lost […]